Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional)
ID: 341117Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/341117

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-198.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting proposals for the Precision Approaches in Radiation Synthetic Combinations (PAIRS) program through the R01 grant mechanism, aimed at developing innovative cancer treatments by investigating synthetic vulnerabilities associated with tumor responses to radiation therapy. This funding opportunity encourages research that explores combined treatment strategies leveraging radiation modalities to enhance tumor-targeting precision, with a focus on pre-clinical studies or early-phase clinical trials. The initiative is critical for advancing precision oncology and improving health outcomes by addressing significant scientific barriers in cancer care. Interested applicants, including higher education institutions, nonprofits, and foreign entities, must submit their proposals by September 7, 2025, and can find additional information at the NIH grants website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-198.html
    The National Cancer Institute (NCI) invites proposals for the Precision Approaches in Radiation Synthetic Combinations (PAIRS) program through the R01 grant mechanism. This initiative aims to develop innovative cancer treatments by exploring synthetic vulnerabilities linked to tumor responses from radiation therapy. Applicants can propose pre-clinical research or early-phase clinical trials to study and validate radiation-synthetic strategies, emphasizing tumor-targeting precision. Key aspects include the exploration of combined treatments that exploit cancer cell vulnerabilities created by radiation, utilizing various radiation modalities. Multi-Principal Investigator applications are encouraged to enhance collaborative efforts across disciplines. Eligible applicants range from higher education institutions to nonprofits and foreign entities, with applications due by specific deadlines based on the NIH schedule. Projects must adhere to the R01 guidelines, showing preliminary data supporting their hypotheses. The funding opportunity emphasizes the integration of novel approaches to optimize the therapeutic index of cancer treatments while addressing crucial scientific barriers. The program fosters advancements in precision oncology, seeking to transform cancer care through research that is responsive to the dynamics of radiation therapy in conjunction with targeted therapies. Overall, this FOA promotes innovative research to improve cancer treatments, aligning with the broader goals of enhancing health outcomes through precision medicine.
    Similar Opportunities
    Precision Approaches in Radiation Synthetic Combinations (PAIRS, R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Precision Approaches in Radiation Synthetic Combinations" (PAIRS) to support R21 research projects focused on identifying actionable vulnerabilities in tumors that respond to radiation therapy. The objective is to develop innovative radiation-synthetic combination strategies that enhance anticancer treatments, with applications ranging from pre-clinical research to early clinical trials. This initiative underscores the significance of precision medicine in oncology and encourages collaborative efforts to address complex cancer challenges. Eligible applicants include various institutions and organizations, with a funding ceiling of $275,000 over two years, and applications are due by September 7, 2025. For more information, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the official announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-199.html.
    Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE)" aimed at advancing research in cancer therapeutics. This initiative invites R01 research project applications that utilize innovative cancer biology methods to investigate the effects of radionuclide-based therapies on normal tissues, tumor cells, and the tumor microenvironment. The STRIPE program is critical for fostering research that may lead to effective treatments for metastatic diseases, emphasizing collaboration among experts in the field while excluding applications focused solely on clinical trials or computational methods. Interested applicants can apply for grants with a budget ceiling of $500,000 per year for a maximum project period of five years, with the application deadline set for May 7, 2025. For further inquiries, applicants may contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-139.html.
    Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)" aimed at supporting collaborative research projects that address the long-term adverse effects of cancer therapies. The initiative seeks to identify and characterize the mechanisms behind therapy-induced adverse sequelae, with a focus on developing therapeutic strategies to prevent or mitigate these chronic comorbidities. This funding opportunity is crucial for enhancing patient quality of life through effective interventions based on mechanistic insights and clinical findings. Interested applicants, including various educational and community organizations, must submit their proposals by November 5, 2024, and can find additional information at the NIH grants website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)" aimed at advancing research in cancer biology and oncology through the application of nanotechnology. This initiative encourages proposals that address significant challenges in these fields by focusing on mechanistic studies of nanomaterial interactions with biological systems, rather than clinical applications. The program is particularly important for enhancing the understanding of nanoparticle delivery mechanisms and improving diagnostic technologies in cancer treatment. Interested applicants can apply for grants with a budget cap of $475,000 per year over a maximum project period of five years, with applications due by May 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-246.html.
    Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Systematic Testing of Radionuclides in Preclinical Experiments" (STRIPE) through the R21 Exploratory/Developmental Research Grant mechanism. This initiative aims to support preclinical research focused on the effects of radionuclide-based therapeutics on normal tissues, tumor cells, and their microenvironments, encouraging collaborative applications that explore innovative therapeutic strategies. The maximum budget for successful proposals is set at $275,000 in direct costs over a two-year period, with applications due by various dates until October 16, 2025. Interested applicants can find additional information and application guidelines at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the National Cancer Institute (NCI) for investigator-initiated early phase clinical trials focused on cancer treatment and diagnosis, specifically under the R01 Research Project Grant mechanism (PAR-24-085). This initiative invites research proposals for Phase 0, I, and II clinical trials that align with the missions of various NCI programs, while explicitly excluding Phase III trials. The program aims to advance cancer research by assessing novel therapeutic and diagnostic interventions, improving imaging technologies, and exploring treatment combinations, with applications encouraged from a diverse range of eligible organizations, including educational institutions and non-profits. Interested applicants should note that the submission deadlines begin on January 5, 2024, with the opportunity closing on January 8, 2027. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-085.html.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional)." This initiative aims to support innovative research projects that integrate advanced imaging techniques, biomarkers, and digital pathomics to enhance the early detection of aggressive cancers and precancerous lesions, thereby improving diagnostic accuracy and reducing overdiagnosis. The program emphasizes the importance of multidisciplinary collaboration in cancer research, particularly focusing on high-risk cancers such as pancreatic and lung cancers. Interested applicants, including higher education institutions, nonprofits, and government entities, must submit their proposals by September 7, 2025, and can find additional information and application details at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research," aimed at advancing innovative research in biomimetic tissue-engineered technologies for cancer. This initiative seeks to support collaborative, multidisciplinary projects that integrate regenerative medicine, tissue engineering, and cancer biology to develop advanced in vitro and ex vivo models that accurately mimic human cancer pathophysiology. The funding opportunity is crucial for enhancing cancer research methodologies and understanding disease mechanisms, with a maximum budget of $400,000 per year and a project duration of up to five years. Interested applicants must submit their proposals electronically via Grants.gov by May 8, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Novel Approaches for Radiation Biodosimetry and Medical Countermeasure Development (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the R21 grant titled "Novel Approaches for Radiation Biodosimetry and Medical Countermeasure Development," aimed at supporting exploratory research projects focused on radiation exposure and its medical countermeasures. The initiative seeks innovative proposals that address the development of biodosimetry techniques, medical countermeasures for radiation injuries, and animal model development, with an emphasis on high-risk, high-reward research that can enhance public health emergency preparedness. The total funding available is approximately $2 million, with individual awards capped at $100,000 per year for a maximum of two years. Interested applicants must submit their proposals by November 1, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.